Abeln Bob G S, van der Graaf Marisa, Musat Dan L, Gunawardene Melanie A, Nair Devi G, Knight Bradley P, Wilsmore Bradley, Liebregts Max, van Dijk Vincent F, Wijffels Maurits C E F, Balt Jippe C, Mittal Suneet, Willems Stephan, Verma Nishant, Peigh Graham, Malaty Michael M, Boersma Lucas V A
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
J Cardiovasc Electrophysiol. 2025 Aug;36(8):1957-1965. doi: 10.1111/jce.16761. Epub 2025 Jun 12.
There are few comparative studies on the everyday clinical outcomes of commercially available pulsed field ablation (PFA) systems for atrial fibrillation (AF).
This study evaluates the acute efficacy and safety outcomes of the FARAPULSE™ (pentaspline catheter) and PulseSelect™ (circular catheter) system.
International, multicenter, registry on patients with paroxysmal or persistent AF, undergoing a first ablation using either PFA system between January 29th, 2024 and September 1st, 2024. Primary endpoints were electrical isolation of ablation targets, procedural characteristics and freedom from major adverse events within 30 days postprocedure.
A total of 402 patients were enrolled at the six participating centers, of whom 56.5% were treated with the pentaspline ablation-catheter. Acute procedural efficacy was 100% for both groups. Use of the pentaspline ablation-catheter was associated with significantly shorter procedural times (36.0 min [IQR 31.0; 44.0] vs. 49.0 min [IQR 41.5;76.0]) compared to the circular ablation-catheter (p < 0.001). Major adverse events were scarce and not different between cohorts. Two patients (0.5%) experienced a stroke and one patient (0.2%) had a serious vascular access site complication. One patient had a transient ischemic attack (0.2%). Minor vascular access site complications were more common in the pentaspline catheter group (11.9% vs. 1.1%, p < 0.001).
This study showed excellent acute efficacy and safety for both PFA-systems. Our findings reveal shorter procedural times with the pentaspline catheter, less minor access site complications with the circular catheter, and several procedural differences between the ablation systems, often driven by operator choice.
关于市售用于心房颤动(AF)的脉冲场消融(PFA)系统日常临床结果的比较研究较少。
本研究评估FARAPULSE™(五棱形导管)和PulseSelect™(圆形导管)系统的急性疗效和安全性结果。
一项国际多中心注册研究,纳入2024年1月29日至2024年9月1日期间首次使用任一PFA系统进行消融的阵发性或持续性AF患者。主要终点是消融靶点的电隔离、手术特征以及术后30天内无主要不良事件。
六个参与中心共纳入402例患者,其中56.5%接受五棱形消融导管治疗。两组的急性手术疗效均为100%。与圆形消融导管相比,使用五棱形消融导管的手术时间显著更短(36.0分钟[四分位间距31.0;44.0] vs. 49.0分钟[四分位间距41.5;76.0])(p < 0.001)。主要不良事件很少,且两组之间无差异。两名患者(0.5%)发生中风,一名患者(0.2%)出现严重的血管入路部位并发症。一名患者发生短暂性脑缺血发作(0.2%)。轻微血管入路部位并发症在五棱形导管组更常见(11.9% vs. 1.1%,p < 0.001)。
本研究表明两种PFA系统均具有出色的急性疗效和安全性。我们的研究结果显示,五棱形导管的手术时间更短,圆形导管的轻微入路部位并发症更少,且消融系统之间存在一些手术差异,这些差异通常由操作者的选择驱动。